ONGC was the top gainer in the Sensex pack, rallying over 13 per cent, followed by HCL Tech, Hero MotoCorp, NTPC, TCS, M&M, Infosys and Maruti.
NSE Nifty soared 306.55 points, or 3.21 per cent, to 9,859.90.
Taking its rising streak to the fourth straight session, equity benchmark Sensex rallied 997 points on Thursday led by gains in energy, IT and banking stocks as positive cues from global markets enthused domestic investors.
Short covering due to expiry of April series F&O contracts added to the momentum, traders said.
Similarly, the NSE Nifty soared 306.55 points, or 3.21 per cent, to 9,859.90.
ONGC was the top gainer in the Sensex pack, rallying over 13 per cent, followed by HCL Tech, Hero MotoCorp, NTPC, TCS, M&M, Infosys and Maruti.
Shares of Reliance Industries and Tech Mahindra climbed around 3 per cent ahead of their earnings announcements, while HUL settled in the red.
Sun Pharma, IndusInd Bank and Asian Paints too closed with losses.
Most major global markets have rallied in the current week as several countries have started to talk about lifting the lockdown, said Sanjeev Zarbade, VP PCG Research, Kotak Securities.
"Reports of encouraging results about Gilead's drug in treating COVID-19 as well as starting of human trials on a vaccine also fuelled the rally," he said.
Top US epidemiologist Anthony Fauci said that Gilead Science's remdesivir "has a clear-cut, significant, positive effect in diminishing the time to recovery".
Bourses in Shanghai and Tokyo ended with significant gains, while those in Hong Kong and Seoul were closed for a holiday.
International oil benchmark Brent crude futures rallied 9 per cent to $26.40 per barrel.
Further, rising buzz of another stimulus package by the government, focused on industries, kept investor sentiment positive, traders said.
Photograph: Reuters
COVID-19: Ayurvedic products are increasingly popular
Worried about your mutual funds? Read this please!
Reliance cuts employees' salary by 10-50%
Raghuram Rajan on how India should lift lockdown
Glenmark to conduct trials of potential COVID-19 drug